Abstract Replication Protein A (RPA) is the major single-stranded DNA (ssDNA) binding protein in the cell and plays a role in replication, recombination, and the DNA damage response (DDR) and repair. RPA functions to protect ssDNA from degradation and also serves as an interaction hub to recruit replication and DDR machinery. Under normal cellular conditions, RPA protein abundance is in excess to that of the ssDNA generated during S phase replication so as to protect from replication fork collapse and replication catastrophe in the event of elevated levels of replication stress. RPA inhibition is thus a promising cancer therapeutic strategy that targets oncogenic cells with increased replication stress due to rapid cell proliferation, genotoxic stressors, DDR inhibition, etc, and therefore an increased ssDNA burden. We have previously developed the RPA inhibitor (RPAi) NERx329 that disrupts RPA-ssDNA binding and exhibits single agent anti-cancer activity in vitro and in vivo presumably due to chemical RPA exhaustion. When a cell experiences extensive replication stress, elevated levels of RPA-bound ssDNA are recognized by the kinase ataxia telangiectasia and Rad2-related (ATR) through the ATR interacting protein (ATRIP). ATR is then activated through interactions with DNA topoisomerase 2-binding protein 1 (TopBP1) and phosphorylates downstream targets largely to direct the G2/M checkpoint signaling pathway through checkpoint kinase 1 (CHK1). In this work, we biochemically reconstitute this signaling pathway in order to evaluate an RPAi mechanism of action. We utilize a ssDNA substrate that mimics a stalled replication fork and demonstrate the RPA-dependence of ATR activation by monitoring phosphorylation of multiple ATR substrates: RPA, TopBP1, and p53. We then show that RPAi disrupt ATR kinase activity. Collectively, this works describes a novel mechanism of action of RPAi whereby RPA inhibition results in replication catastrophe by blocking the ATR activity and the G2/M checkpoint pathway. Citation Format: Matthew R Jordan, Diana Ainembabazi, Pamela S VanderVere-Carozza, Navnath S Gavande, Katherine S Pawelczak, John J Turchi. Small molecule RPA inhibitors abrogate the ATR kinase signaling pathway [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr B052.
Read full abstract